Cocrystal Pharma, Inc. (COCP): Entry into a Material Definitive Agreement
Cocrystal Pharma, Inc. (COCP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026 BOTHELL, Wash., August 3, 2026 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (N
How this was made
The 30-second read
Why it matters
For traders, the key is whether this agreement implies a near-term equity issuance that could dilute existing holders. The agreement references a purchase price tied to Nasdaq consolidated bid, but the actual per-share price and number of shares are not shown in the provided text.
Market read
A material definitive agreement for an unregistered equity sale is disclosed, creating potential dilution and financing overhang expectations until final terms are known.
What to watch
The excerpt omits the share quantity and the final purchase price, which are critical to assessing dilution, cash proceeds, and likely follow-on selling pressure.
Background
The SEC 8-K discloses entry into a securities purchase agreement (Item 1.01) and unregistered sales of equity securities (Item 3.02), including representations about authorization and Nasdaq listing.
Ticker impact
COCP entered a securities purchase agreement with OPKO Health to sell shares of COCP common stock under a material definitive agreement.
Near-term volatility risk is elevated around closing details, but direction depends on the final share count and discount versus market, which are not provided here.
The filing confirms a material definitive agreement and unregistered equity sale structure, but the key economic terms (share quantity and exact purchase price) are redacted in the provided text.
Market effects
Signals ongoing financing activity in small-cap biotech, which can pressure sentiment for similarly capital-constrained issuers.
Limited, primarily affects US small-cap biotech risk appetite.
Low, as this is a bilateral equity transaction with no cross-border operational disclosure in the excerpt.
Counterpoint
If the issuance is priced at or above Nasdaq bid with no meaningful discount, the dilution overhang may be smaller than typical financings.
Key entities
- issuerCocrystal Pharma, Inc.
Subject of the 8-K, entering a securities purchase agreement to sell common stock to a named purchaser.
- purchaserOPKO Health, Inc.
Purchaser under the securities purchase agreement for COCP common stock.